Article

Classification of sleep-disordered breathing.

Division of Pulmonary and Critical Care Medicine, New York University School of Medicine, New York, New York, USA.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 03/2001; 163(2):398-405. DOI: 10.1164/ajrccm.163.2.9808132
Source: PubMed

ABSTRACT Increasing recognition of sleep-disordered breathing (SDB) and its morbidity have prompted reevaluation of techniques to identify respiratory events during sleep. The present study was designed to evaluate the utility of various metrics of SDB and to identify the optimal respiratory metric that objectively correlates to symptoms of excessive daytime somnolence (EDS). Metrics were derived from combinations of conventional apnea/hypopnea, flow limitation events (transient elevated upper airway resistance identified by characteristic flattening on the flow/time tracing, using a noninvasive nasal cannula technique), desaturation, and arousal. A total of 137 subjects underwent clinical evaluation and nocturnal polysomnogram. In 34 randomly selected subjects, the best metrics for discriminating between 13 subjects with no EDS/snoring and 21 patients with EDS and snoring were identified by receiver operator curve analysis. Of the metrics and cut points tested, a total respiratory disturbance index (RDI(Total), sum of apneas, hypopnea, and flow limitation events) of 18 events/h was found to have the best discriminant ability (100% sensitivity and 96% specificity). Prospective testing of this metric was then performed with the remaining 103 subjects (14 nonsnoring non-EDS, 21 snoring non-EDS, 68 snoring with EDS). Using this cutoff of 18 events/h, we obtained 71% sensitivity and 60% specificity for identifying subjects with EDS. We conclude that, in subjects with upper airway dysfunction, an index that incorporates all respiratory events provides the best quantitative physiological correlate to EDS.

0 Followers
 · 
186 Views
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: To confirm the efficacy and safety of recombinant human α-L-iduronidase (laronidase) in patients with mucopolysaccharidosis I (MPS I).Study designThis was a randomized, double-blinded, multinational study of 45 patients with MPS I administered 100 U/kg (0.58 mg/kg) laronidase, or placebo intravenously weekly for 26 weeks. The coprimary efficacy end points compared the median change from baseline to week 26 between groups in percentage of predicted normal forced vital capacity (FVC) and in 6-minute walk test (6MWT) distance through the use of the Wilcoxon rank sum test.ResultsThe laronidase (n = 22) and placebo (n = 23) groups had similar baseline characteristics. After 26 weeks, patients receiving laronidase compared with placebo showed mean improvements of 5.6 percentage points in percent of predicted normal FVC (median, 3.0; P = .009) and 38.1 meters in 6MWT distance (median, 38.5; P = .066; P = .039, analysis of covariance). Laronidase also significantly reduced hepatomegaly and urinary glycosaminoglycans, and, in more severely affected patients, improved sleep apnea/hypopnea and shoulder flexion. Laronidase was well-tolerated. Nearly all patients receiving enzyme had development of IgG antibodies, without apparent clinical effects.Conclusions In patients with MPS I, laronidase significantly improves respiratory function and physical capacity, reduces glycosaminoglycan storage, and has a favorable safety profile.
    Journal of Pediatrics 05/2004; 144(5):581-588. DOI:10.1016/S0022-3476(04)00091-5 · 3.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Continuous maintenance of an appropriate position of the mandible and head purely by manual manipulation is difficult, although the maneuver can restore airway patency during sleep and anesthesia. The aim of this paper was to examine the effect of head elevation with jaw closure using a remote-controlled airbag device, such as the airbag system, on passive upper airway collapsibility during propofol anesthesia. Seven male subjects were studied. Propofol infusion was used for anesthesia induction and maintenance, with a target blood propofol concentration of 1.5–2 (mu ) g/ml. Nasal mask pressure ( ({P}_{text {N}}) ) was intermittently reduced to evaluate upper airway collapsibility (passive ({P}_{_{text {CRIT}}}) ) and upstream resistance ( ({R}_{_{text {US}}}) ) at three different head and jaw positions, jaw opening position in the supine position, jaw opening position in the sniffing position with 6-cm head elevation, and jaw closure at a 6-cm height sniffing position. The 6-cm height sniffing position with jaw closure was achieved by an airbag device that was attached to the subject’s head-like headgear. Patient demographics, ({P}_{_{text {CRIT}}}) and ({R}_{_{text {US}}}) in each condition were compared using one-way ANOVA with a post hoc Tukey test. ({rm P}<0.05) was considered significant. We also confirmed the effects of our airbag device on improvement of upper airway collapsibility in three obstructive sleep apnea patients in a clinica- study. The combination of 6-cm head elevation with jaw closure using the air-inflatable robotic airbag system decreased upper airway collapsibility ( ({P}_{_{text {CRIT}}}sim -3.4) -cm H (_{2}) O) compared with the baseline position ( ({P}_{_{text {CRIT}}}sim -0.8) -cm H (_{2}) O, ({P} = 0.0001) ). In the clinical study, there was improvement of upper airway obstruction in sleep apnea patients, including decreased apnea and hypopnea duration and increased the lowest level of oxygen saturation. We demonstrated that establishment of head elevation with jaw closure achieved by a remote-controlled airbag device using an inflatable airbag system can produce substantial decreases in upper airway collapsibility and maintain upper airway patency during propofol anesthesia and sleep.
    01/2014; 2:1-9. DOI:10.1109/JTEHM.2014.2321062